Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Grows By 64.4%

SOPHiA GENETICS SA (NASDAQ:SOPH) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 61,800 shares, a growth of 64.4% from the February 13th total of 37,600 shares. Based on an average daily volume of 74,500 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.1% of the shares of the company are sold short.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently bought and sold shares of SOPH. Principal Financial Group Inc. boosted its stake in shares of SOPHiA GENETICS by 6.3% during the third quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock valued at $5,290,000 after purchasing an additional 86,764 shares in the last quarter. Green Alpha Advisors LLC boosted its position in SOPHiA GENETICS by 119.3% during the 4th quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock worth $145,000 after buying an additional 25,686 shares during the period. Silverberg Bernstein Capital Management LLC bought a new stake in SOPHiA GENETICS during the 4th quarter worth approximately $70,000. Millennium Management LLC increased its position in SOPHiA GENETICS by 6.5% in the 4th quarter. Millennium Management LLC now owns 698,634 shares of the company’s stock valued at $2,180,000 after acquiring an additional 42,689 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of SOPHiA GENETICS by 23.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company’s stock valued at $68,000 after acquiring an additional 4,115 shares during the last quarter. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Price Performance

NASDAQ SOPH traded up $0.10 on Friday, hitting $3.22. 30,934 shares of the company’s stock were exchanged, compared to its average volume of 69,599. The stock has a 50-day moving average of $3.58 and a 200-day moving average of $3.54. The stock has a market cap of $214.73 million, a price-to-earnings ratio of -2.95 and a beta of 1.01. SOPHiA GENETICS has a 52 week low of $2.70 and a 52 week high of $6.28. The company has a current ratio of 3.80, a quick ratio of 3.59 and a debt-to-equity ratio of 0.12.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.23) earnings per share for the quarter, meeting the consensus estimate of ($0.23). The business had revenue of $17.73 million for the quarter, compared to analyst estimates of $17.71 million. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. Analysts expect that SOPHiA GENETICS will post -0.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on SOPH shares. BTIG Research set a $5.00 price target on SOPHiA GENETICS in a research note on Thursday, March 6th. Craig Hallum began coverage on SOPHiA GENETICS in a research report on Wednesday, December 18th. They issued a “buy” rating and a $11.00 price target on the stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.